Business
AstraZeneca Shares Slide on Reports of a Possible $400B Bristol Myers Megamerger
A Financial Times report of merger talks sent AstraZeneca stock lower as analysts questioned why the fast-growing company would take on such a deal. Neither firm has confirmed.